Conference abstractPublished 7 Sep 2018
Hepatitis B in focus: New biology, new targets and real hope for fi nite therapy
Arrowhead Pharmaceuticals Inc., USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Drug development work in Chronic Hepatits B (CHB) has been largely stagnant for the last decade or more. While solid epidemiology work has demonstrated that seroclearance of HbsAg (functional cure) is associated with greatly reduced risk of cirrhosis or HCC, neither interferon therapy nor long-term nucleos(t)ide therapy are associated with meaningful rates of functional cure. With the recent successes achieved in curative treatment of Hepatitis C, the field has returned to curative eff orts in CHB and there has been an explosion of pre-clinical drug development against novel targets. As part of this process, new insights have been gained regarding the biology of CHB. This talk will focus on how these new biological insights are translating into new drug discovery eff orts, how these new drug classes are performing in the clinic, and the expected role for combining these drugs to achieve meaningful rates of functional cure with finite therapy.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectGastroenterology & Hepatology
- SubjectInfectious Diseases
- BylineArticles whose byline prints “Bruce D Given”